Meriofert

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular and subcutaneous use. It treats infertility related to anovulation, hypogonadotropic hypogonadism, and supports assisted reproductive technology protocols in the European Union market.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert, a gonadotropin used in reproductive endocrinology, is indicated for: - Infertility due to anovulation: stimulates follicular growth to enable ovulation. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal gonadal function. - Assisted reproductive technology (ART) protocols: supports controlled ovarian stimulation in IVF cycles. - Ovarian stimulation in donor cycles: facilitates oocyte retrieval for donation programs.

Adverse reactions reported with Meriofert may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Abdominal bloating: transient sensation of fullness. - Mild ovarian hyperstimulation: increased follicle size without severe symptoms. - Headache: occasional tension‑type headache. - Nausea: mild, self‑limiting gastrointestinal upset. - Fluid retention: mild peripheral edema.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, abdominal pain, and respiratory distress. - Multiple pregnancy: increased risk of twins or higher order gestations. - Thromboembolic events: rare clot formation in veins. - Allergic reactions: rash, urticaria, or anaphylaxis. - Ectopic pregnancy: implantation outside the uterus. - Severe abdominal pain: may indicate ovarian torsion or rupture.

Before initiating Meriofert therapy, clinicians should consider several safety measures. - Baseline assessment: evaluate ovarian reserve and hormonal profile. - Monitoring: regularly measure estradiol levels and follicle size during treatment. - Cyst exclusion: avoid use in patients with active ovarian cysts. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications that affect reproductive hormones or coagulation.

Major Interactions (Avoid): - Aromatase inhibitors: may blunt estrogen response to treatment. - GnRH antagonists: can reduce the efficacy of gonadotropin stimulation. - High‑dose estrogen therapy: increases risk of excessive ovarian stimulation.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter timing of ovarian stimulation cycles. - Anticoagulants: monitor for bleeding at injection sites. - Other gonadotropins: concurrent use may heighten hyperstimulation risk.